parkin

Parkin (PRKN / PARK2)

An E3 ubiquitin ligase of the RBR (RING-between-RING) family that serves as the principal effector of damage-selective mitophagy. In healthy cells Parkin resides in the cytosol in an auto-inhibited conformation; upon mitochondrial membrane-potential collapse, pink1 stabilized on the outer mitochondrial membrane (OMM) phosphorylates both ubiquitin (Ser65-Ub) and Parkin’s own ubiquitin-like domain (Ser65-UbL), sequentially releasing auto-inhibition and unleashing E3 activity. Active Parkin then ubiquitinates dozens of OMM-resident proteins (≥36 confirmed MOM proteins; hundreds of ubiquitylation sites identified proteomically ¹), building a polyubiquitin coat that cargo receptors (NDP52, OPTN) use to recruit the autophagosome. Loss-of-function mutations in the PRKN gene cause autosomal recessive juvenile Parkinsonism (PARK2) — the most common monogenic form of Parkinson’s disease — establishing that Parkin-mediated mitophagy is non-redundant for dopaminergic neuron survival ².

Identity

• UniProt: O60260 (PRKN_HUMAN)
• NCBI Gene: 5071
• HGNC symbol: PRKN (formerly PARK2)
• Mouse ortholog: Prkn (one-to-one ortholog)
• Length: 465 amino acids (canonical isoform) needs-canonical-id — UniProt API unavailable at seeding; confirm 465 aa on next lint pass
• Molecular weight: ~52 kDa
• Gene locus: chr6q25.2-q27 (one of the largest human genes at ~1.4 Mb)

Domain organization

Parkin’s domain architecture is the mechanistic basis for its auto-inhibition and stepwise activation ³:

Domain	Residues (approx.)	Function
Ubl (ubiquitin-like)	1–76	Resembles ubiquitin; Ser65 phosphorylated by PINK1; key auto-inhibitory contact with RING1; releases from RING1 upon phosphorylation 4
Disordered linker	77–140	Flexible, least-conserved region connecting Ubl to RING0; intrinsically disordered in crystal structures 4
RING0 (also called UPD)	~141–225	Unique-Parkin domain; structural; binds Zn²⁺ ions; makes auto-inhibitory contacts with RING2 and buries Cys431 4
RING1	~226–326	Binds E2-ubiquitin conjugates (UbcH7/UBE2L3); contains the pUb-binding site (His302/Arg305) on its surface opposite to the Ubl-binding helix 4
IBR (in-between-RING)	~327–378	Structurally bridges RING1 and RING2; common to all RBR ligases; intrinsically flexible 4
REP (repressor element of Parkin)	~378–410	Occludes the E2-binding surface of RING1 in the auto-inhibited state; displaced upon Ubl phosphorylation 4
RING2	~410–465	Catalytic RING; houses active-site Cys431 (the thioester-accepting cysteine); occluded by RING0 in the inactive state 4

The crystal structure of full-length Parkin in the auto-inhibited state was solved by Trempe et al. 2013 and independently by Riley et al. 2013, revealing how four inter-domain contacts cooperate to sequester Cys431 ³.

Auto-inhibition and activation mechanism

In basal conditions, three principal autoinhibitory contacts maintain Parkin in an inactive conformation ³:

1. Ubl–RING1 contact — the UbL domain occludes the RING1 E2-binding surface.
2. REP–RING1 contact — the REP helix (~383-410) covers the E2 docking site on RING1.
3. RING0–RING2 contact — RING0 sequesters Cys431 of RING2, preventing thioester bond formation.

PINK1-mediated sequential activation

On healthy mitochondria, PINK1 is constitutively imported, cleaved by the inner-membrane protease PARL, and retrogradely degraded — keeping cytosolic PINK1 near zero. When membrane potential (ΔΨm) collapses, import stalls and PINK1 accumulates on the OMM surface ⁵. Stabilized PINK1 then initiates a two-hit activation of Parkin:

Hit 1 — Phospho-ubiquitin (phospho-Ub). PINK1 phosphorylates Ser65 on pre-existing ubiquitin chains on the OMM. Phospho-Ub (pS65-Ub) binds a site on RING1 of cytosolic Parkin, formed by His302 and Arg305, on the face of RING1 opposite to the Ubl-binding helix ⁴. This binding competes with Ubl for RING1 occupancy through negative allostery — displacing the Ubl domain and initiating auto-inhibition relief ⁴. no-fulltext-access — Koyano 2014 (not_oa) characterised the phospho-Ub feed-forward loop; the specific RING1 binding site was resolved by Wauer 2015.

Hit 2 — Direct Parkin phosphorylation. PINK1 directly phosphorylates Parkin at Ser65 within the UbL domain. Phospho-UbL can no longer maintain the inhibitory contact with RING1, fully releasing the REP element and opening the RING2 active site ⁴.

Both hits are required for maximal activation: phospho-Ub binding provides initial recruitment and partial activation, while direct Ubl phosphorylation provides the conformational change needed for Cys431 engagement ⁴. A feed-forward amplification loop results: active Parkin ubiquitinates OMM substrates → PINK1 phosphorylates the new ubiquitin chains → more Parkin is recruited from the cytosol ⁶.

E3 catalytic mechanism

Parkin operates as an RBR E3 ligase via a RING-HECT hybrid mechanism:

1. E1 (UBA1) loads ubiquitin onto E2 (UBE2L3 / UBE2D family).
2. RING1 recruits the E2~Ub thioester via the E2 docking site.
3. Ubiquitin is transferred as a thioester to Parkin Cys431 (RING2), forming an enzyme-bound intermediate.
4. Ubiquitin is then delivered to a Lys residue on the substrate via aminolysis.

Unlike HECT ligases, Parkin’s thioester intermediate is transient and the substrate identity is specified by RING1 docking contacts, not a HECT-type C-lobe ³. Parkin generates both K48 (proteasomal degradation) and K63 (autophagy receptor recruitment) polyubiquitin chains, with chain type partly dependent on the E2 used.

OMM substrates and downstream events

Sarraf et al. 2013 used quantitative diGLY-capture proteomics (QdiGLY / SILAC) to map the Parkin-dependent ubiquitylome in HCT116 and HeLa cells after CCCP-induced depolarization, identifying hundreds of ubiquitylation sites in dozens of proteins, with ≥36 confirmed MOM-resident proteins among 60 high-confidence Class 1/2 targets ¹. Functionally important substrate classes:

Substrate	Consequence of ubiquitination
MFN1, MFN2 (mitofusins)	K48-linked polyUb → p97/VCP-mediated extraction → proteasomal degradation; prevents re-fusion of damaged mitochondrion with healthy network 7
MIRO1, MIRO2 (Rho GTPases)	Ubiquitination → degradation → mitochondria detach from microtubule tracks (motor proteins KIF5/TRAK released); prevents trafficking away from autophagosomal machinery needs-replication — mechanistic detail mainly from cell lines
VDAC1	K27-linked polyubiquitination (predominantly) → p62/SQSTM1 recruitment; VDAC1 is required for Parkin translocation and final mitochondrial clearance 8
TOMM20, TOMM70	Ubiquitination of TOM complex components; further impairs import and aids in flagging the organelle
HK1, HK2 (hexokinases)	Ubiquitination identified proteomically; 14 Class 1/2 diGLY sites detected across both globular domains of HK1; functional consequence of HK1/2 OMM displacement not fully characterised 1

Geisler et al. 2010 demonstrated that Parkin-mediated VDAC1 ubiquitination (K27-linked chains, primarily) is required for robust p62 recruitment and efficient mitophagy flux in HeLa and SH-SY5Y neuronal cells; siRNA knockdown of VDAC1 significantly reduced both Parkin translocation and final mitochondrial clearance ⁸.

After ubiquitination, the autophagy receptors NDP52 and OPTN (optineurin) — which contain both UBA (ubiquitin-association) domains and LIR (LC3-interacting region) motifs — bridge the poly-Ub coat to LC3-II on growing autophagosome membranes, driving engulfment of the targeted mitochondrion (see mitophagy for receptor-level detail).

Role in Parkinson’s disease

Discovery and genetic evidence

Kitada et al. 1998 identified PRKN mutations in Japanese families with autosomal recessive juvenile parkinsonism (AR-JP), characterized by onset before age 40, selective dopaminergic neuron loss in the substantia nigra, and Lewy body-negative pathology (typically) ². The paper identified large deletions across the PRKN gene in affected individuals in a Nature paper that has accumulated >5,100 citations. PARK2 is now the most common cause of monogenic PD worldwide, with compound heterozygous loss-of-function variants responsible for a substantial proportion of early-onset PD cases.

The genetic implication is unambiguous: Parkin-mediated mitophagy is non-redundant for dopaminergic neuron survival in humans. No compensatory pathway fully substitutes when Parkin function is lost.

Dimension	Status
Pathway conserved in humans?	yes — PRKN encodes a human protein; AR-JP is the human loss-of-function phenotype
Phenotype conserved in humans?	yes — dopaminergic neuron degeneration is the cardinal PD phenotype in PRKN-null humans
Replicated in humans?	yes (genetic epidemiology; multiple independent families/ethnic groups)

Parkin in sporadic PD and aging

The connection extends beyond Mendelian PD: Parkin protein levels and activity decline with aging in the brain and other post-mitotic tissues, paralleling the broader age-related decline in mitophagy flux ⁹. S-nitrosylation and oxidative modification of Parkin Cys residues in aged neurons may contribute to loss of activity even without genetic mutation — a potential mechanistic link between age-related nitrosative stress, mitophagy impairment, and sporadic PD risk. no-mechanism — the in-vivo quantitative contribution of oxidative Parkin inactivation to sporadic PD is not established.

Aging context — Parkin overexpression extends lifespan

Rana et al. 2013 showed that ubiquitous or pan-neuronal overexpression of Parkin in Drosophila melanogaster extends both mean and maximum lifespan (ubiquitous daGS>UAS-parkin: ~28% increase in both mean and maximum lifespan in female flies; log-rank, n > 200 female flies per group), reduces the accumulation of insoluble ubiquitin-conjugated protein aggregates with age, and alters mitochondrial dynamics toward fission (reduced dMfn levels, increased mitochondrial fragmentation) ¹⁰. Parkin OE also increased citrate synthase activity and respiratory complex I/II activity, suggesting functional mitochondrial improvement. These findings suggest that augmenting Parkin activity above basal levels is sufficient to delay aging-associated proteotoxicity and mitochondrial dysfunction in flies.

Dimension	Status
Pathway conserved in humans?	yes — PRKN is a human gene; mammalian Parkin function is conserved
Phenotype conserved in humans?	unknown — lifespan extension not tested in mice or humans
Replicated in humans?	no needs-human-replication

Notably, Parkin overexpression studies in mice are less conclusive: transgenic Parkin mice show improved mitochondrial function in some metabolic contexts but no consistent longevity phenotype has been reported in aged mice. needs-replication

Pathway membership

• pink1-parkin-pathway — the dedicated damage-sensing mitophagy arm; Parkin is the effector E3 ligase
• mitophagy — process page; Parkin-mediated ubiquitination drives cargo-receptor docking and autophagosome recruitment
• autophagy — parent process; Parkin-tagged mitochondria are degraded via the core autophagy machinery
• ubiquitin-proteasome-system — Parkin-generated K48 chains on MFN1/2 are resolved by the proteasome, not autophagy

Key interactors

• pink1 — upstream serine/threonine kinase; stabilizes on OMM under depolarization; phosphorylates both ubiquitin Ser65 and Parkin Ser65 to sequentially activate Parkin
• mfn1, mfn2 — OMM fusion GTPases; primary Parkin substrates for K48 polyUb and proteasomal degradation
• miro1, miro2 — mitochondrial Rho GTPases; Parkin ubiquitination releases microtubule anchoring
• vdac1 — voltage-dependent anion channel; ubiquitinated by Parkin; recruits p62/SQSTM1
• optn — autophagy receptor; binds Parkin-generated polyUb chains via UBA domain; LIR motif engages LC3
• ndp52 — autophagy receptor; redundant with OPTN in PINK1/Parkin-mediated mitophagy
• p62 — autophagy receptor/scaffold; binds Parkin-generated polyUb (K63) via UBA; supplementary role

Disease and pharmacology

• Parkinson’s disease (AR-JP / PARK2) — loss-of-function PRKN mutations; most common monogenic PD form; see parkinsons-disease (implicit stub)
• No approved PRKN-targeted therapy exists. Efforts to pharmacologically reactivate Parkin focus on: (1) releasing auto-inhibition allosterically; (2) reducing oxidative/nitrosative modification of Cys residues. Several small-molecule Parkin activators are in preclinical development. long-term-unknown
• Parkin and cancer: PRKN behaves as a tumor suppressor in some contexts (its locus 6q25 is among the most frequently deleted in human cancers); the connection is hypothesized to involve mitochondrial quality control and metabolic reprogramming — mechanistically unresolved. no-mechanism

Limitations and gaps

• Age-related decline of Parkin protein and activity in human post-mitotic tissues is documented in small studies only. needs-replication
• Whether augmenting Parkin (via gene delivery or small-molecule activation) extends healthspan or lifespan in mice has not been definitively established. needs-human-replication
• The contribution of Parkin to basal (non-depolarization-triggered) mitophagy in vivo is contested; most mechanistic work uses CCCP depolarization, a pharmacological insult not equivalent to physiological mitophagy. no-mechanism
• MIRO1/2 ubiquitination by Parkin and the consequent mitochondrial trafficking arrest is mechanistically well-described in cell lines but has limited direct in-vivo confirmation in aged tissue. needs-replication
• Sporadic-PD S-nitrosylation inactivation of Parkin in aged human brain needs quantitative in-vivo validation. no-mechanism

Related pages

• pink1 — upstream kinase partner (implicit stub — seed next in round 6b)
• pink1-parkin-pathway — dedicated pathway page (implicit stub)
• mitophagy — verified-partial; parent process
• autophagy — verified-partial; parent process
• ubiquitin-proteasome-system — downstream proteasomal arm for MFN1/2 K48 substrates (implicit stub)
• parkinsons-disease — disease context (implicit stub)
• miro1 — Parkin substrate; mitochondrial trafficking anchor (implicit stub)
• mfn1, mfn2 — Parkin substrates; OMM fusion proteins (implicit stubs)
• vdac1 — Parkin substrate; OMM channel (implicit stub)
• optn — cargo receptor downstream of Parkin (implicit stub)
• ndp52 — cargo receptor downstream of Parkin (implicit stub)
• mitochondrial-dysfunction — hallmark driven by failed mitophagy

Footnotes

Footnotes

1. doi:10.1038/nature12043 · in-vitro (QdiGLY proteomics / SILAC) · model: HCT116^PARKIN and HeLa^PARKIN cells · Sarraf, Raman, Guarani-Pereira et al. (Harper lab) 2013 Nature · landscape-scale diGLY-capture proteomics of the Parkin-dependent ubiquitylome after CCCP-induced depolarization; identifies hundreds of ubiquitylation sites in dozens of proteins; 36 confirmed MOM proteins among 60 Class 1/2 high-confidence targets including MFN1/2, RHOT1/2 (MIRO1/2), VDAC1/2/3, HK1/HK2, TOMM20, TOMM70; complementary AP-MS identifies interaction partners; local PDF available (author manuscript) ↩ ↩² ↩³

2. doi:10.1038/33416 · in-vivo (human genetics) · n=N/A (pedigree genetic study, multiple Japanese families) · Kitada et al. 1998 Nature · original identification of PRKN mutations in autosomal recessive juvenile parkinsonism; large deletions identified in affected individuals; >5,100 citations · archive: not_oa ↩ ↩²

3. doi:10.1126/science.1237908 · in-vitro (X-ray crystallography) · Trempe et al. 2013 Science · first crystal structure of full-length human Parkin in auto-inhibited conformation; resolves the four inter-domain contacts that sequester Cys431; 519 citations · archive: not_oa ↩ ↩² ↩³ ↩⁴

4. doi:10.15252/embj.201592237 · in-vitro (crystallography + SAXS + ITC + NMR + biochemical) · Sauvé, Lilov, Seirafi et al. (Trempe & Gehring labs) 2015 EMBO J · presents Delta86-130 Parkin crystal structure at 2.54 Å; shows pUb binds RING1 at His302/Arg305 (opposite face from Ubl-binding helix); demonstrates Ubl phosphorylation (pUbl) releases Ubl from RING1 and increases UbcH7 binding affinity; both pUb and pUbl are required for maximal Parkin E3 activity; local PDF available ↩ ↩² ↩³ ↩⁴ ↩⁵ ↩⁶ ↩⁷ ↩⁸ ↩⁹ ↩¹⁰ ↩¹¹

5. doi:10.1083/jcb.200809125 · in-vitro · model: HeLa cells, HEK293 cells, mouse MEFs, rat cortical neurons · Narendra et al. 2008 J Cell Biol · foundational study showing Parkin is selectively recruited to depolarized mitochondria and promotes their autophagic degradation; establishes Parkin-dependent, ATG5-dependent mitophagy; does not characterize the PINK1 kinase mechanism or phospho-ubiquitin (those were discovered 2014) · local PDF available ↩

6. doi:10.1038/nature13392 · in-vitro · model: HeLa cells + biochemical reconstitution · Koyano et al. 2014 Nature · demonstrates that ubiquitin phosphorylated at Ser65 by PINK1 (phospho-Ub) directly activates Parkin; establishes the phospho-Ub feed-forward amplification loop; 1,435 citations · archive: not_oa ↩

7. doi:10.1083/jcb.201007013 · in-vitro · model: SH-SY5Y neuroblastoma cells (endogenous Parkin) + HeLa cells (YFP-Parkin) + MEFs · Tanaka, Cleland, Xu, Narendra, Suen, Karbowski & Youle 2010 J Cell Biol · demonstrates Parkin-dependent ubiquitination of MFN1 and MFN2 upon CCCP treatment; Mfn degradation requires p97/AAA+ ATPase; both p97 and proteasome activity required for Parkin-mediated mitophagy; Parkin-mediated mitofusin loss prevents re-fusion; inhibition of Drp1-mediated fission or p97 blocks Parkin-induced mitophagy; local PDF available ↩

8. doi:10.1038/ncb2012 · in-vitro · model: HeLa cells + SH-SY5Y neuronal cells · Geisler, Holmström, Skujat, Fiesel, Rothfuss, Kahle & Springer 2010 Nat Cell Biol · shows PINK1 kinase activity and MTS are prerequisites for Parkin translocation; Parkin mediates K27- and K63-linked polyubiquitin chain formation on mitochondria; identifies VDAC1 as a Parkin ubiquitination substrate via K27-linked chains predominantly; VDAC1 knockdown abrogates both Parkin translocation and mitochondrial clearance; p62/SQSTM1 recruitment to clustered mitochondria requires VDAC1 ubiquitination; local PDF available ↩ ↩²

9. doi:10.15252/embj.2020104705 · review · model: multi-system · Onishi, Yamano, Sato, Matsuda & Okamoto 2021 EMBO J · comprehensive review covering PINK1/Parkin mechanism, receptor-mediated arms, aging decline of mitophagy, neurodegeneration context · local PDF available (see mitophagy footnotes) ↩

10. doi:10.1073/pnas.1216197110 · in-vivo · model: Drosophila melanogaster (daGS>UAS-parkin ubiquitous OE; Elav>UAS-parkin neuronal OE; mifepristone-inducible) · Rana, Rera & Walker 2013 PNAS · ubiquitous Parkin OE extends both mean AND maximum lifespan (~28% increase in female flies; log-rank, n > 200 per group); reduces insoluble ubiquitin-conjugated protein aggregates in aged flies; reduces dMfn levels and promotes mitochondrial fragmentation; increases citrate synthase activity and respiratory complex I/II activity; no major physiological tradeoffs (feeding, physical activity, fecundity); local PDF available ↩